Man Group PLC Assembly Biosciences, Inc. Transaction History

Man Group PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$3.8 - $4.56 $189,240 - $227,087	-49,800 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$4.33 - $6.63 $507,155 - $776,545	-117,126 Reduced 70.17%	49,800 $229,000
Q4 2020 Feb 16, 2021	BUY	$4.87 - $17.29 $514,759 - $1.83 Million	105,700 Added 172.64%	166,926 $1.01 Million
Q3 2020 Nov 16, 2020	BUY	$15.08 - $27.04 $306,124 - $548,912	20,300 Added 49.6%	61,226 $1.01 Million
Q2 2020 Aug 14, 2020	SELL	$14.57 - $23.96 $27,683 - $45,524	-1,900 Reduced 4.44%	40,926 $954,000
Q1 2020 May 15, 2020	SELL	$10.27 - $21.23 $20,540 - $42,460	-2,000 Reduced 4.46%	42,826 $635,000
Q4 2019 Feb 18, 2020	BUY	$8.36 - $23.81 $374,745 - $1.07 Million	44,826 New	44,826 $917,000
Q2 2019 Aug 14, 2019	SELL	$12.9 - $20.8 $983,302 - $1.59 Million	-76,225 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$17.7 - $24.93 $664,192 - $935,498	37,525 Added 96.96%	76,225 $1.5 Million
Q4 2018 Feb 14, 2019	BUY	$19.05 - $36.45 $50,634 - $96,884	2,658 Added 7.37%	38,700 $875,000
Q3 2018 Nov 14, 2018	BUY	$34.41 - $44.23 $203,156 - $261,133	5,904 Added 19.59%	36,042 $1.34 Million
Q2 2018 Aug 14, 2018	BUY	$39.21 - $50.29 $1.18 Million - $1.52 Million	30,138 New	30,138 $1.18 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $723M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.